Q-omics provides the consensus-scored TTC6 profile across patient tissues and cancer cell-line models. TTC6 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TTC6 is differentially expressed in 13, with the highest sampling consensus in BRCA. Additionally, TTC6 RNA expression shows 16,275 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRC, and BRCA as cancer lineages where TTC6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTC6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTC6 survival associations across molecular data types. TTC6 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTC6 RNA expression–survival associations across cancer types. High TTC6 expression shows unfavorable associations in KIRC, KIRP, ACC and MESO, but favorable associations in BRCA and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TTC6 RNA expression.
This table summarizes TTC6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in LUSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TTC6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTC6 shows lower tumor expression in LUSC, HNSC and COAD and higher tumor expression in BRCA, LIHC and PRAD. The BRCA box plot shows higher TTC6 RNA expression in tumor versus normal tissue (log2 FC = +0.430, t-test p = .017).
This table shows molecular features associated with TTC6 in patient tissues and cancer cell lines. In patient samples, TTC6 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, TTC6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SKIN.
